Original Research ArticleInternational Journal of Reproduction, Contraception, Obstetrics and Gynecology
Publication: Comparison of neonatal birthweights and fetomaternal outcomes in gestational diabetes-on diet, metformin and insulin
Int J Reprod Contracept Obstet Gynecol. 2022;11(7):1998-2003.DOI10.18203/2320-1770.ijrcog20221684
Abstract
Background Review suggested that neonatal birthweight in insulin group was higher than in metformin and diet and metformin had overall better fetomaternal outcomes. We wanted to understand the trend in the patients visiting our hospital.
Methods This is an observational comparative study conducted in Department of Obstetrics and Gynaecology, AIMS Kochi from 2019-2021. All antenatal patients were screened and total of 153 patients meeting inclusion and exclusion criteria were studied. The data was collected and analysed using SPSS 20 software.
Results The neonatal birthweight the three groups were comparable, with no significant difference (3.05±0.42 kgs in diet; 2.92±0.37 kgs in metformin; 3.11±0.41 kgs in insulin; p=0.092) and maternal pre-pregnancy weight was associated with birthweight. Insulin group had higher age (31.17±5.54 years versus 27.59±4.62 years in OHA and 29.43±4.56 years in diet; p<0.001). Insulin group delivered at an earlier gestation (37 weeks versus 38 weeks; p<0.001) and most common mode of delivery was cesearean section (74.6% in insulin; 54.2% in diet and 49.8% in OHA). NICU admission (45.8% versus 10.8% in diet and 15.4% in OHA; p<0.001) and need for phototherapy (1.5% in metformin versus 5.4% in diet and 11.8% in insulin; p=0.067) was lesser in metformin group.
Conclusions Strict glycemic control is important in preventing macrosomia Metformin overall has good fetomaternal outcomes compared to diet or insulin.
Keywords
Affiliations
- Department of Obstetrics and Gynecology, Kerala, India
- Department of Biostatistics, Amrita Institute, Kerala, India
